tbuckley/cabot-search huggingface dataset:
Dietary intake of broccoli and the risk of cancer in the prostate, lung, colorectal, and ovarian cancer (PCLO) screening trial.
Authors: Robert J. Thomas, Alex McConnachie, Madeleine M A Williams, Bethany Stanley
Journal: Journal of Clinical Oncology (2020)

e13560 Background: The cruciferous vegetable broccoli, are a good source of vitamins, minerals and fibre, as well as thiol phytochemicals (indole-3-carbinol), glucosinolates (isothiocyanates, its metabolite, sulforaphane), carotenoids (lutein and zeaxanthin) and flavonols (kaempferol). Laboratory and human biopsy studies have found that broccoli intake influenced epigenetic expression of genes via blockage of histone deacetylase which reduce inflammation and cancer growth. Clinically, a randomised control study reported dried broccoli extract (along with three other foods) influenced PSA progression in men with prostate cancer 1 . However, no preventative intervention studies in humans have been conducted and data from cohort studies are inconsistent for its influence on cancer incidence 2,3 . Methods: We analysed 49,104 people within the intervention arm of the 155,000 participant PLCO screening trial. Histological confirmed cases of any cancer were reported in 8,263 (16.83%) during the 11.5 year follow up. Broccoli consumption was assessed with a food frequency questionnaire (FFQ). Baseline characteristics were compared between broccoli consumption groups using Chi-square and Kruskal-Wallis tests. Cox regression models were used to assess the association between broccoli intake and cancer incidence. Results: Broccoli consumption was associated with reduced cancer incidence: HR 0.95 (CI 0.93-0.97, p &lt; 0.001). This pattern persisted with adjustments for age, sex, race, education level and family history (HR 0.97, CI 0.96-0.99, p = 0.007) as well as smoking, BMI and alcohol consumption (HR 0.98, CI 0.96-0.99, p = 0.010). Conclusions: The study identified an association between increased broccoli consumption and reduced cancer risk. In practical terms, 15g of broccoli, or more, consumed per day (about a small cup) was associated with a 5% lower risk of cancer. Broccoli should continue to be included in healthy eating advice. This data supports the consideration of future prospective intervention studies investigating the role of broccoli as part of a cancer prevention programme. References 1. Thomas et al. The NCRN Pomi-T RCT. Prostate cancer &amp; prostatic diseases (2014), 2,180. 2. Liu et al Cruciferous vegetables inversely linked with breast cancer: Breast (2013), 22;3,309. 3. Bosetti et al Cruciferous vegetables and cancer risk Ann Oncol (2012) 23(8);2198.
Association of PD-L1 expression with hotspot mutations in non-small cell lung cancer (NSCLC).
Authors: Renping Wan, Xiaoni Zhang, Hongyue Qu, Hui Li, Yingmei Li, Mingyan Xu, Yun Xiao
Journal: Journal of Clinical Oncology (2020)

e21604 Background: PD-L1 is of great interest in many clinical trials on immunotherapy as a promising biomarker, however, its role in targeted therapy and correlation with hotspot mutations remains unclear. Methods: From May 6th 2019 to Jan 27th 2020, 609 NSCLC patients were prospectively enrolled. Targeted deep sequencing (~3000X) with a 605-gene panel was performed on tumor and blood sample from each patient. The expression of PD-L1 was tested by immunohistochemistry. PD-L1 expression level was defined as negative ( &lt; 1%), low (1%~50%), and high (≥50%). Results: In the total 609 patients, the expression of PD-L1 was negative in 36.9% (n = 256), low in 51.7% (n = 315) and high in 11.3% (n = 69) of them. In 440 patients harboring hotspot mutations, 35.0% (n = 154) of them were identified as PD-L1 negative, 52.3% (n = 230) as PD-L1 low and 12.7% (56/440) as PD-L1 high. In 169 patients without hotspot mutations, there were 42.0% (71/169) of patients with negative PD-L1 expression, 50.3% (85/169) with low PD-L1 expression and 7.7% (13/169) with high PD-L1 expression. Mutation frequencies of several hotspot mutations were summarized in Table. Conclusions: This study showed that PD-L1 expression was associated with some hotspot mutations, such as BRAF_p.V600E, KRAS_p.G12/G13/Q61 and amplification of MET. Although the biological mechanism of this association is yet to be investigated, combination of hotspot mutations and PD-L1 expression could be a future direction in biomarker studies. [Table: see text]
Community-based family intervention improves symptom and social function of schizophrenic patients
Authors: Jing Tang, Ke-ming Wu, De-an Liu, Jian-jun Li, Shu-bing Qiu, Qing Zhou
Journal: BMJ (2013)

One hundred and twenty patients with schizophrenia were randomly divided into intervention group and the control group with 60 in each. Family members in intervention group were given community based-rehabilitation training and education once a month for 12 months. Brief Psychiatric Rating Scale (BPRS) and Social Disability Screening Schedule (SDSS) were used to assess the symptoms and social function of patients before and after intervention. The results were compared between two groups. Results showed that the BPRS total score and the SDSS total score in intervention group were lower than those in control group (P<0.05). The training and education of family members can improve symptoms and functional recovery for patients with schizophrenia.


Key words: 
Schizophrenia; Community mental health services
Comparing and assessing the reported penetrance of cancer susceptibility genes for breast cancer.
Authors: Kanhua Yin, Danielle Braun, Ankur Tiwari, Jin Wang, Preeti Singh, Jingan Zhou, Giovanni Parmigiani, Kevin S. Hughes
Journal: Journal of Clinical Oncology (2020)

1520 Background: It is critical for oncologists to be aware of unbiased and interpretable cancer risks (i.e., penetrance) in carriers with germline pathogenic variants in cancer susceptibility genes. However, relevant literature is large and varies significantly in study design, patient ascertainment, and types of risk estimates reported. This heterogeneity can cause inconsistent conclusions between studies and create barriers for clinicians to understand and apply them in practice. To further understand the current literature, we assessed penetrance studies associated with non-BRCA breast cancer susceptibility genes based on study design and ascertainment adjustment. Methods: We used a validated natural language processing-based abstract classifier to identify all penetrance studies regarding eleven genes: ATM, BARD1, CDH1, CHEK2, NBN, NF1, PALB2, PTEN, RECQL, STK11, and TP53. Relevant studies were then manually annotated as “with ascertainment adjustment” if a study was based on: (1) a general population; (2) a pedigree analysis or a family-based study with appropriate ascertainment adjustment; or (3) a hospital-based study or a panel testing analysis with well-matched cases and controls. Results: A total of 49 penetrance studies were identified, with a median of nine studies for each gene (range: 4-16). The case-control study was the dominant study type, accounting for over 80% in five genes, 50% in two genes, and 18% to 43% in the other four genes. The proportion of studies with ascertainment adjustment was generally low (mean: 33%) and varied widely between different genes (7% to 80%). Contradictory breast cancer risks (no increased risk vs. significantly increased risk) were found in eight genes (73%) (Table). The most common ascertainment bias identified was a case-control study with cases (patients) who had a strong family history but using general population controls. Conclusions: Ascertainment bias is common in penetrance studies, but few studies adjust for it appropriately. Clinicians should be aware of this issue, and new methods are warranted to select unbiased risk estimates, synthesize them, and provide the accurate general-population penetrance. [Table: see text]
Predicting prostate cancer death among 98,994 veterans: Differences by race/ethnicity.
Authors: Tate Janet, Ioana Danciu, Amy Justice, Michael Leapman, Benjamin McMahon, Roxanne Wadia
Journal: Journal of Clinical Oncology (2020)

e17609 Background: Prostate cancer mortality is higher in Blacks than Whites, but existing prognostic indices fail to account for race/ethnicity. Using data from the national U.S. Veterans Affairs Healthcare System (VA), we compared prediction of prostate cancer death by race/ethnicity. Methods: Men with biopsy confirmed prostate cancer from 2002-2016 were included. We excluded those with lymph node or distant metastatic disease at diagnosis and those not classified as Non-Hispanic White (NHW), Non-Hispanic Black (NHB), or Hispanic (HSP). We set aside 20% for future validation. Cox models estimated hazard ratios (HR) for prostate cancer death, stratified by age and race/ethnicity. Each was adjusted for age, Gleason score, tumor (T) stage, PSA at diagnosis, and calendar year. Results: Among 98,994 veterans with localized disease, 64% were NHW, 30% were NHB, and 6% were HSP. At diagnosis, median age differed by race/ethnicity (NHW 66 [IQR 62-71] yrs.; NHB 63 [58-68] yrs.; HSP 66 [61-73] yrs.). During follow-up 23,316 men died, 3484 (15% overall, and by race/ethnicity) by prostate cancer. Among those &lt; 65 yrs at diagnosis, HR for Gleason score were much stronger among NHW than NHB; associations for PSA level were stronger among NHB than NHW. HRs for HSP and NHW were similar. T stage HRs were similar by age and race/ethnicity. Conclusions: Risk associated with Gleason score and PSA varied by age and race/ethnicity. Prognostic models for prostate cancer disease progression must be evaluated in diverse populations and across age strata. [Table: see text]
胺碘酮治疗婴儿心肌炎并发室性心动过速一例
Authors: 韩佩孚, 张海涛, 王景山, 杨秀亭
Journal: BMJ (2011)

患儿男，2个月，因腹泻4～5d，面色苍白、多汗6h于2010年10月28日入院。病初发热1次，体温未测，大便为黄绿色稀水样便，日约3～4次。体检：体温36.7℃，脉搏243次/min，呼吸34次/min，体重5.5 kg。神志清，精神萎靡，无脱水貌，呼吸平稳，全身皮肤无花纹、无黄染、无皮疹及出血点，皮肤弹性尚可，前囟无凹陷，无鼻翼扇动，口唇轻微紫绀，咽稍充血；颈软，气管居中，吸气三凹征（一），双肺呼吸音粗，无啰音；心率243次/min，心音有力，各瓣膜听诊区未闻及杂音；腹软，肝右肋下2.5 cn，质地软，剑下未及，脾未及；肠鸣音存在，四肢末端暖，脉搏欠有力，双下肢轻度浮肿。 关键词：心肌炎
脓毒症并甲状旁腺危象一例
Authors: 寿松涛, 柴艳芬, 崔书章
Journal: BMJ (2005)

全球脓毒症发病率高达3‰,每年发病人数超过1 800万例,成为抢救危重病的临床医师关注的热点.甲状旁腺危象发病率相对较低,但也呈逐年增加趋势.脓毒症合并甲状旁腺危象罕见,现将我科收治的1例报告如下。
胰头部恶性淋巴瘤一例
Authors: 景华, 刘华, 凌贞, 李明峰, 吴兆麟, 曹金龙
Journal: BMJ (2004)

患者男,66岁,因皮肤、巩膜黄染伴发热、消瘦2月于2002年11月12日入院.患者于2个月前无明显诱因出现右上腹部闷胀不适,伴有乏力、纳差,皮肤、巩膜黄染,小便色深,如浓茶样,大便为陶土样,并有皮肤瘙痒,午后低热(具体体温不详),无盗汗,无咳嗽、咳痰,无尿频、尿急、尿痛等.于外院B超提示:胆总管及肝内胆管壁增厚,伴局部胆管狭窄扩张,胆总管内胆泥淤积,胰腺光点增粗;CT提示:胆总管下段狭窄,胰头增大;肝功能示丙氨酸转氨酶(ALT)102 U/L,天冬氨酸转氨酶(AST)76 U/L,乳酸脱氢酶(LDH)185 U/L,总胆红素(TB)53.5 μmol/L,直接胆红素(DB)36.1 μmol/L.经消炎利胆治疗病情无好转,进一步行逆行胰胆管造影(ERCP)检查提示:胆总管胰头段偏心性充盈缺损、胰头段胰管狭窄,肝内胆管细线样狭窄.诊断为胰腺癌致阻塞性黄疸可能.放置鼻胆管于左肝内胆管,引流通畅,但黄疸进行性加深,一般情况差而收入我院。
Status of treatment for atrial fibrillation in a community health service center in Shanghai Pudong New Area
Authors: Lan Ni, Jinhua Xue
Journal: BMJ (2019)

Objective
To analyze the status of the treatment for atrial fibrillation (AF) in a community health service center in Shanghai Pudong New Area.


Methods
Clinical data of all patients with AF attended in Hudong Community Health Service Center of Shanghai Pudong from August 2016 to August 2017 were retrospectively reviewed. The gender, age, smoking history, drinking history, concomitant diseases, antithrombotic therapy, rhythm control, ventricular rate control drugs, health education, needs for setting up AF clinics in the community were analyzed.


Result
The study included 220 patients, with average age of (59.7±10.4) years; 34.1% (75/220) patients had hypertension and the blood pressure was controlled in 41.3% (31/75) ; 20.5% (45/220) patients had diabetes mellitus and glycosylated hemoglobin (HbA1c) was controlled well in 26.7% (12/45) . Three cases of mitral stenosis were treated with warfarin anticoagulation. Among 217 patients without valvular atrial fibrillation, 157 had thromboembolic risk score≥2, 20.4% (32/157) of whom used warfarin anticoagulation, 10.8% (17/157) used new oral anticoagulant (NOAG) and 58.1% (91/157) had never used warfarin or NOAG anticoagulation. The reasons were as follows:doctors did not prescribe (41.9%, 39/91), patients did not accept (35.2%, 32/91), and so on. There were 21.8% (48/220) of patients undergoing drug cardioversion, and 5.9% (13/220) undergoing electrical cardioversion. For control of ventricular rate, 55.9% (123/220) patients used beta blockers, 13.6% (30/220) used non-dihydropyridine calcium antagonists, and 23.6% (52/220) used digitalise. Less than 55% of patients were given health education of physical exercise, weight management and medicine use. For AF clinic in community hospital, 56.8% (125/220) of patients needed, and 17.3% (38/220) very need; 50.0% (110/220) patients trusted and 12.3% (27/220) very trusted in anticoagulation management in community hospitals.


Conclusion
The anticoagulant rate is relatively low, treatment of concomitant diseases is less satisfactory and the health education might be incomplete in the community surveyed in this study.


Key words: 
Atrial fibrillation; Community health services; General practitioner; Treatment
HIV postexposure prophylaxis during COVID-19
Authors: Muhammad Junejo, Nicolo Girometti, Alan McOwan, Gary Whitlock, Keerti Gedela, Nicolo Girometti, Sheena McCormack, Alan McOwan, Diarmuid Nugent, Sheel Patel, Tara Suchak, Victoria Tittle, Gary Whitlock
Journal: The Lancet HIV (2020)

PEPSE=postexposure prophylaxis following sexual exposure
Prevalence of fatty liver in a district of Shanghai detected by B-type ultrasonography and serum activity of alanine aminotransferase
Authors: 蔡晓波, 范建高, 朱军, 李新建, 李锐, 戴菲
Journal: BMJ (2007)

目的 通过B超和ALT检测探讨上海浦东新区成人脂肪肝的患病率及其危险因素.方法 采用随机多级分层整群抽样方法,抽取浦东新区4个居委会16岁以上2017例居民,调查内容有问卷咨询、体格检查、75 g葡萄糖耐量试验、血脂和血ALT检测以及肝脏实时超声检查,对ALT升高者进一步检测HBsAg.根据脂肪肝检出和ALT水平分为脂肪肝和(或)ALT升高组430例,对照组1587例.结果 B超和ALT升高联合诊断,上海市浦东新区成人脂肪肝患病率为21.32%(430/2017).与对照组比较,脂肪肝组腹型肥胖率为26.34%对71.16%、高甘油三酯血症为12.73%对71.16%、低高密度脂蛋白胆固醇血症为4.79%对11.86%、原发性高血压为39.57%对66.74%、糖调节受损为24.01%对35.58%、糖尿病为6.81%对24.40%、代谢综合征为11.28%对47.21%.多元logistic回归分析显示,体重指数(OR=1.080)、餐后2 h血糖(OR=1.149)、舒张压(OR=1.035)、甘油三酯(OR=1.526)、腹型肥胖(OR=1.960)、糖尿病(OR=1.391)是发生脂肪肝的独立危险因素.结论 上海市浦东新区成人脂肪肝的患病率较高;脂肪肝与糖代谢和脂代谢紊乱密切相关。
Dietary advanced glycation end products (AGEs) and breast cancer mortality in the women’s health initiative (WHI).
Authors: Lindsay Leuthen Peterson, Omonefe Omofuma, David P Turner, Anwar Merchant, Jiajia Zhang, Marian L. Neuhouser, Linda Snetselaar, Bette Jane Caan, Aladdin H. Shadyab, Nazmus Saquib, Cynthia A. Thomson, Jaime Uribarri, Susan Steck
Journal: Journal of Clinical Oncology (2020)

1570 Background: Breast cancer (BrCa) is the second leading cause of cancer death and constitutes about 14% of total cancer deaths among US women. Advanced glycation end-products (AGEs) are implicated in chronic diseases including cancer and cardiovascular diseases (CVD). AGEs are naturally found in animal products and processed foods, and preparing food at high temperatures increases AGE formation. Our goal was to assess the association between post-diagnosis dietary N Ɛ -carboxymethyl-lysine (CML)-AGE intake, a common measure of AGE, and mortality from all-causes, BrCa and CVD among participants with invasive BrCa in the Women’s Health Initiative (WHI). Methods: The WHI enrolled postmenopausal women aged 50 to 79 years from 1993-1998 into randomized controlled trials and a prospective observational study to examine causes of morbidity and mortality. In this analysis, we included 2,073 women diagnosed with invasive BrCa during follow-up who completed a food frequency questionnaire (FFQ) after diagnosis, had energy intakes between ≥600 kcal/day and ≤5000 kcal/day, and had CML-AGE intake data available. Women were followed from BrCa diagnosis until death or censoring through March 2018. Cox proportional hazards regression models estimated the hazard ratios (HR) and 95% CIs of mortality risk from all-causes, BrCa and CVD by tertiles of dietary CML-AGE intake with adjustment for age, income, race/ethnicity, study arm, time from diagnosis to FFQ completion, education, physical activity, smoking, BMI, ER/PR status, diagnosis stage, postmenopausal hormone use, intake of energy, alcohol, fat, red and processed meats. Results: After a median 15.1 years of follow-up, 642 deaths were reported including 198 BrCa-specific and 129 CVD-specific deaths. The average time from BrCa diagnosis to FFQ completion was 1.5 years. Compared to the lowest tertile of CML-AGE intake, there was an increased risk in the highest tertile for all-cause mortality (HR : 1.51, 95% CI: 1.17-1.94), BrCa (HR: 1.86, 95% CI: 1.19-2.91) and CVD (HR: 2.14, 95% CI: 1.19-3.84) mortality. Conclusions: Higher dietary AGE intake after BrCa diagnosis in postmenopausal women was associated with increased risk of mortality from all-causes, BrCa and CVD. Exposure to AGEs could be modified through dietary counseling and evaluated in relation to reduced mortality risk after BrCa diagnosis.
Anorectal neuroendocrine carcinoma (NEC): Patient characteristics and treatment outcomes.
Authors: Benjamin Edward Ueberroth, Alex John Liu, Thorvardur Ragnar Halfdanarson, Mohamad Bassam Sonbol
Journal: Journal of Clinical Oncology (2020)

e16702 Background: There are only a few reports examining the treatment patterns for poorly differentiated rectal/anal NEC. In this study, we sought to report treatment and survival outcomes for patients with NEC of the anus and rectum seen at Mayo Clinic. Methods: We identified patients with a primary NEC of the anus or rectum using Mayo Clinic databases (Minnesota, Arizona, Florida) from the year 2000 to present. NEC identified within polyps on colonoscopy was excluded from this study. Patients’ demographics were compiled. Kaplan Meier analyses were performed to evaluate overall survival (OS) for all patients, as well as subgroups with locoregional disease (LRD) and metastatic disease at diagnosis. Progression free survival (PFS) was also evaluated for patients with LRD treated with chemoradiation therapy (CRT). Results: 38 patients with NEC of the anus/rectum were identified with a median age of 55.5 years. 23 patients (61%) had metastatic disease at diagnosis and 15 (39%) had LRD. The most common site of metastasis was the liver (n = 20). Patients with metastatic disease at presentation had significantly shorter OS compared to patients with LRD (median OS 10.4 vs. 18.9 months, p = 0.039; HR 2.46, 95% CI [1.001-6.050]). 34 total patients received chemotherapy (ORR 11.8%), with platinum + etoposide (EP) being the most common first-line chemotherapy (n = 26). 10 of 15 patients with LRD received CRT (9 with EP and 1 with 5-FU) with median PFS of 6.3 months (95% CI 2.3-16.5 months), a 1-year PFS rate of 20%, and median OS of 18.6 months (95% CI 13.5-23.7 months). 2/10 received induction chemotherapy prior to CRT with 6/10 undergoing primary tumor resection (1 prior to CRT and 5 after CRT). Only 3 CRT patients were living at time of analysis (all underwent surgical resection), 2 without any active disease, 1 who achieved complete response with CRT then suffered recurrence and is still undergoing treatment. Conclusions: NEC of the anus and rectum is an aggressive malignancy with most patients experiencing metastatic disease at presentation and poor response to chemotherapy at all stages. Even those with LRD experience a very poor prognosis with OS of 18.9 months from diagnosis. For LRD, most patients underwent CRT with only a short-lived response (median PFS 6.3 months). Those achieving sustained response also underwent surgical resection. Overall, prognosis is poor for all stages and further study on a large scale is warranted to better characterize this rare, aggressive malignancy.
警惕低血糖发作
Authors: 金世红
Journal: BMJ (2007)

有一天下午我在急诊室值班,15:00左右有一位患者被导诊护士推入急诊室.患者为62岁男性,身体消瘦,意识不清,呼之不应,血压正常,全身皮肤湿冷,双目凝视,两侧瞳孔轻微散大,约4 mm,对光反射迟钝,有自主呼吸,12次/min,双肺呼吸音清,无干湿哕音,心率92次/min,律齐,无杂音,四肢检查不能合作.我当时迅速考虑:脑血管意外?低血糖昏迷?患者的妻子在一旁说当天上午她的丈夫因左侧肢体无力在我院神经内科就诊,医生建议其行头颅CT检查,做完检查后已近中午,检查报告要在下午取,故她和患者二人就在医院门诊大厅内等候。
SPRING: A Worldwide Innovative Network (WIN) Consortium phase I study of triple therapy (avelumab, axitinib, and palbociclib) in advanced non-small cell lung cancer (NSCLC) with genomic and transcriptomic correlates.
Authors: Benjamin Maurice Solomon, Ana Callejo, Jair Bar, Guy J. Berchem, Lyudmila Bazhenova, Pierre Saintigny, Eric Raymond, Nicolas Girard, Raed Sulaiman, Bruce Prouse, Catherine Bresson, Fanny Wunder, J. Jack Lee, Jacques Raynaud, Eitan Rubin, Vladimir Lazar, Enriqueta Felip, Amir Onn, Brian Leyland-Jones, Razelle Kurzrock
Journal: Journal of Clinical Oncology (2020)

9581 Background: The Worldwide Innovative Network (WIN) Consortium has developed the Simplified Interventional Mapping System (SIMS) algorithm in order to predict treatment response by comparing tumor and normal tissue biopsies on both genomic and transcriptomic platforms. SPRING is the first trial to assess a SIMS-based tri-therapy regimen in advanced non-small cell lung cancer (NSCLC). Methods: Patients with advanced NSCLC (no EGFR or ALK alterations; no ROS1 alterations if tested; PD-L1 unrestricted; ≤2 prior therapy lines) were treated with avelumab, axitinib, and palbociclib (3+3 dose escalation design). Tumor and normal endobronchial mucosal biopsies were obtained on all patients for retrospective SIMS algorithm validation. Results: Fifteen patients were treated: 6 at dose level 1 (DL1); 6, dose level 2 (DL2); 3, dose level 3 (DL3). Three dose-limiting toxicities (DLTs) at least possibly drug-related occurred: 1 DLT at DL2 (Grade 3 (G3) infusion reaction); 2 patients with DLTs at DL3 (1 with G3 hand/foot syndrome and G3 fatigue and 1 with G5 respiratory failure). Among 14 evaluable patients, the partial response (PR) rate was 28.6% (4/14 patients including 2/6 patients at DL1; two PRs in patients who failed prior pembrolizumab; two PRs in patients with PD-L1 &lt; 1%). The maximum tolerated dose was avelumab 10 mg/kg IV q2weeks, axitinib 5 mg PO BID continuous, palbociclib 75 mg PO daily on days 8-28 of a 28 day cycle (DL2). DL2 was above the recommended phase II dose (RP2D), since 5/6 patients treated at DL2 required later treatment delays and/or dose reductions, mostly due to neutropenia. To further evaluate DL1, 3 patients were added to this cohort (total of 6). Since no DLTs were seen at DL1, and 5 of 6 patients did not require dose reduction, DL1 (avelumab 10 mg/kg IV q2weeks, axitinib 3 mg PO BID continuous, palbociclib 75 mg PO daily on days 8-28 of a 28 day cycle) is the RP2D. Conclusions: The RP2D was determined to be dose level 1. This triplet showed antitumor activity in patients with NSCLC, including those progressing on prior pembrolizumab. SIMS algorithm correlates of response are being assessed. Clinical trial information: NCT03386929 .
红皮病的识别与治疗
Authors: 晋红中
Journal: BMJ (2010)

红皮病又称剥脱性皮炎,可以累及全身多个系统,是一种严重的系统性疾病.银屑病、皮炎湿疹等因处理不当或治疗不及时会发展成红皮病;抗生素、巴比妥类、抗疟药等药物过敏也会导致红皮病;淋巴网状系统肿瘤,如蕈样肉芽肿、T细胞淋巴瘤性红皮病(Sezary综合征)、霍奇金淋巴瘤、白血病等均是红皮病的病因。